All You Need to Know About CanFite Biopharma Ltd (CANF) Rating Upgrade to BuyZacks Investment Research • 07/26/22
Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe PsoriasisBusiness Wire • 07/11/22
Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT™ Study in Moderate to Severe PsoriasisBusiness Wire • 06/29/22
Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific JournalBusiness Wire • 06/09/22
Can-Fite Reports First Quarter 2022 Financial Results & Provides Clinical UpdateBusiness Wire • 05/26/22
Can-Fite's CEO to Present Namodenoson's Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy SummitBusiness Wire • 05/02/22
Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model: Potential Complementary Product to its Phase III Oral Psoriasis DrugBusiness Wire • 04/05/22
Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022Business Wire • 03/28/22
Can-Fite: Namodenoson's Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent OfficeBusiness Wire • 03/14/22
Can-Fite's Findings in the Treatment of Liver Diseases with Cannabinoids to be Presented at CannX Medical Cannabis Conference in Tel AvivBusiness Wire • 03/11/22
Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with NamodenosonBusiness Wire • 01/31/22
Is CanFite Biopharma Ltd (CANF) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 01/17/22
Prior to Phase III Psoriasis Data Release Can Fite Reports that Piclidenoson Destroys Pathological Skin Cells in vitroBusiness Wire • 01/13/22
Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare ConferenceBusiness Wire • 01/10/22
Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Various Advanced Solid TumorsBusiness Wire • 12/29/21